healthy control participants L73.2 L40 L20 L44.0 L80 L43
Conditions
Interventions
Group 1: not applicable (no AMG / MPG based study)
Study procedures:
- Taking of skin and blood samples from patients with Acne inversa and for comparison from patients with other chronic, inflammat
Sponsors
Charité Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - patients with Acne inversa, other chronic inflammatory skin diseases or healthy participants respectively - age: = 18 years - blood Hb > 10 g/dl (exept if residual material obtained from excision surgery or diagnostic biopsies is used) - willingness to comply with study procedures (taking of skin biopsies) - written, informed consent was given
Exclusion criteria
Exclusion criteria: - age: <18 years, - persons, who are not able to give wrtitten informed consent, - pregnancy or breast feeding, - intake of medication that influences blood ,coagulation the last 10 days before the planned procedures (taking of blood or skin samples), - known allergies against local anesthesia, patches or latex/gloves, - known acute or chronic infectious diseases (e.g. influenza, HIV, HCV, HBV, Covid-19 - known malignancies, - anamnestic hints to exuberant formation of scars or keloids, - person, who are in the physician´s view not able to fulfill the study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoints of the study are: 1) Identification and characterization of the molecular and cellular features contributing to the development and persitence of skin alterations of Acne inversa patients. 2) Testing of novel therapeutic approaches using skin model systems of Acne inversa. | — |
Secondary
| Measure | Time frame |
|---|---|
| Main secondary endpoints of the study are: 1) identification of molecular and cellular differences between lesional versus non-lesional skin of Acne inversa patients, 2) identification of molecular and cellular differences between non-lesional skin of Acne inversa patients versus skin of healthy participants, 3) identification of molecular and cellular differences between lesional skin of Acne inversa patients versus skin of healthy participants, 4) identification of molecular and cellular differences between lesional / non-lesional skin of Acne inversa patients and those of other chronic inflammatory skin diseases 5) correlation of molecular and cellular features of lesional / non-lesional skin of patients among each other and with anamnestic, demopraphic, physiological and clinical data of the patients, 6) characterization of penetration depth of neutralizing /inhibiting substances (e.g. antibodies) in ex vivo cultivated skin models. | — |
Countries
Germany
Contacts
Public ContactKerstin Wolk
Charité Universitätsmedizin BerlinKlinik für Dermatologie, Venerologie & Allergologie und Institut für Medizinische Immunologie
Outcome results
None listed